Market Overview

UPDATE: Piper Jaffray Raises PT to $48 on Medtronic on Solid Quarter, Conservative Guidance

Related MDT
Top 4 NYSE Stocks In The Medical Appliances & Equipment Industry With The Highest Revenue
US Stock Futures Climb Ahead Of Fed's Beige Book
IRS, Eh? Tim Hortons Deal Could Lower Burger King's Tax Bill (Fox Business)

Piper Jaffray reiterated its Overweight rating on Medtronic (NYSE: MDT) and raised its price target from $45 to $48.

Piper Jaffray noted, "While FY13 revenue guidance increased from 2%-4% to 3%-4%, guidance assumes a deceleration in sequential 2H13 growth (vs. 5% cc growth in F1H13). We view this as conservatism on the part of MDT's CEO, and believe this is appropriate given macro headwinds and product specific challenges. GMs were softer than expected, despite strong revenues, perpetuating the discussion on the leverage sustainability, especially given MDT's focus on EM growth. However, we note that the lower end of guidance did come up, and appreciate the renewed focus on meeting expectations. Overall, we view the results as positive."

Medtronic closed at $41.81 on Tuesday.

Latest Ratings for MDT

DateFirmActionFromTo
Sep 2014Sterne AgeeInitiates Coverage onNeutral
Aug 2014CitigroupMaintainsBuy
Aug 2014CitigroupMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MDT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters